Atrium Acquires Douglas Laboratories Canada
Atrium Biotechnologies Inc., Quebec, Canada, has acquired the assets of London, Ontario, Canada-based Douglas Laboratories Canada (DL Canada). DL Canada has been marketing Douglas Laboratories products in Canada since 2000 and has current annual revenues of approximately $5 million. The acquisition provides Atrium with a platform to develop the Canadian healthcare professional market, not only for the Douglas Laboratories brand, but also for the Pure Encapsulations brand, which is not currently being sold in Canada. Atrium will also be able to benefit from the expertise and support of DL Canada’s current management and staff who are staying on to ensure the successful integration and to sustain its growth.